文献速递血液透析通路

肾移植后移除未感染动静脉瘘是安全且有益的处理策略:针对废弃透析通路

Removal of Noninfected Arteriovenous Fistulae after Kidney Transplantation is a Safe and Beneficial Management Strategy for Unused Dialysis Access.
PubMed 文献 · Ann Vasc Surg · 2018-06-08

单中心2006至2016年回顾性分析114例动静脉瘘切除患者,其中36例(31.6%)为肾移植受者。移植组最常见切除指征为动脉瘤样退变(9例,25%),30例(83.3%)移植肾功能完好者中2例(6.7%)术后需透析,2例(5.6%)出现术后并发症。作者认为切除有症状的废弃动静脉瘘安全,现有维持无症状透析通路的策略应重新考虑。

要点

  • 肾移植后废弃动静脉瘘可出现动脉瘤样退变、疼痛、窃血综合征、血栓、高心输出量心衰等指征。
  • 移植肾功能完好者切除瘘后仅2例(6.7%)需透析,2例(5.6%)出现术后并发症。
  • 作者认为现有维持无症状透析通路的策略应重新考虑。

核心结论

  • 移除有症状的废弃动静脉瘘在肾移植受者中可安全施行,现有维持无症状透析通路的策略应重新考虑。

研究设计与样本

  • 单中心回顾性研究,纳入2006年至2016年所有行动静脉瘘切除的患者,其中肾移植后切除者36例(31.6%)进入分析。

主要发现

  • 移植组切除时瘘中位年龄为1903天(四分位距:556-3394天)。
  • 切除指征包括动脉瘤样退变9例(25%)、疼痛6例(16.7%)、上肢窃血综合征5例(13.9%)、血栓5例(13.9%)、高心输出量心力衰竭4例(11%)、静脉高压继发肢体肿胀2例(5.6%)。
  • 30例(83.3%)移植肾功能完好,切除时平均肌酐1.6 mg/dL、eGFR 52.3 mL/min/m2;其中2例(6.7%)肌酐分别为2.0和9.7 mg/dL,切除后需透析,其余28例维持正常肾功能且术前症状改善。
  • 2例(5.6%)出现术后并发症:1例血肿需清除、1例浅表伤口感染需口服抗生素。

临床怎么用

  • 作者认为,考虑到大型动静脉瘘相关并发症(包括高输出量心力衰竭),对肾功能正常的肾移植受者维持无症状透析通路的现有策略应重新考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal transplant recipients often maintain their hemodialysis access in the event of future allograft failure. Patients may develop complications related to the unused dialysis access, and it also limits vein availability for phlebotomy. Accordingly, a change in the current paradigm may be warranted. This study evaluates the indications for, and safety of, arteriovenous fistula (AVF) removal in patients after successful renal transplantation. METHODS: All patients who underwent AVF excision at a single institution from 2006 to 2016 were retrospectively reviewed. Within that cohort, those undergoing removal after renal transplantation were included for analysis. Baseline patient characteristics, including renal function at the time of removal, reason for excision, and age of the AVF, were examined. The primary outcome was the need for dialysis after AVF removal. RESULTS: A total of 114 patients, of which 36 (31.6%) were recipients of renal transplants, underwent fistula removal during the study period. Within the transplant cohort, the median fistula age at the time of excision was 1,903 days (interquartile range: 556-3,394 days). The most common indications for excision included aneurysmal degeneration (n = 9, 25%), pain (n = 6, 16.7%), upper extremity steal syndrome (n = 5, 13.9%), thrombosis (n = 5, 13.9%), high cardiac output heart failure (n = 4, 11%), and extremity swelling secondary to venous hypertension (n = 2, 5.6%). Most patients (30, 83.3%) had intact graft function. Average creatinine and eGFR at the time of excision in these patients were 1.6 mg/dL and 52.3 mL/min/m2, respectively. Two of these 30 patients (6.7%), who had creatinine values of 2.0 and 9.7 mg/dL, went on to require dialysis following excision. The remaining 28 have maintained normal renal function with improvement in their preoperative symptomatology. Two patients (5.6%) experienced postoperative complications-a hematoma requiring evacuation and a superficial wound infection requiring oral antibiotics. CONCLUSIONS: Removal of symptomatic, unused AVFs can be performed safely in renal transplant recipients. Considering the morbidity associated with large AVFs (including high output cardiac failure), the current paradigm of maintaining asymptomatic hemodialysis access in patients with normally functioning renal transplants should be reconsidered.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Fraser CD, Grimm JC, Liu RH, et al. Removal of Noninfected Arteriovenous Fistulae after Kidney Transplantation is a Safe and Beneficial Management Strategy for Unused Dialysis Access. Ann Vasc Surg. 2018. PMID: 29886220. doi:10.1016/j.avsg.2018.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。